Paricalcitol reduces proteinuria in non-dialysis chronic kidney disease patients

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 4, 2013, Pages 368-372

  Hojs, Nina ^a   Bevc, Sebastjan ^a   Balon, Breda Pečovnik ^b   Hojs, Radovan ^a   Ekart, Robert ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY OF MARIBOR   (Slovenia)

Author keywords

Ambulatory blood pressure monitoring; Chronic kidney disease; Paricalcitol; Proteinuria

Indexed keywords

ALBUMIN; CALCIUM; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL PRACTICE; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; GLOMERULONEPHRITIS; HUMAN; KIDNEY POLYCYSTIC DISEASE; MALE; MICROALBUMINURIA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; SECONDARY HYPERPARATHYROIDISM; SYSTOLIC BLOOD PRESSURE;

AMBULATORY BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; PARICALCITOL; PROTEINURIA;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BONE DENSITY CONSERVATION AGENTS; CREATININE; ERGOCALCIFEROLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS;

EID: 84881524486     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12080     Document Type: Article

References (22)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
2. Chadban SJ, Briganti EM, Kerr PG etal. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 2003;14(7 Suppl 2):S131-138.
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
4. Levey AS, de Jong PE, Coresh J etal. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80:17-28.
5. Albuminuria and chronic kidney disease: Key concepts and the potential role of selective vitamin D receptor activation. In: De Zeeuw D, Levey A, eds. Third International Symposium on Albuminuria. The Prognostic Role of Albuminuria. Impact on Kidney and Cardiovascular Outcomes. Groningen: National Kidney Foundation; 2011.
6. Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. Int J Nephrol 2011;2011:419524.
7. Cannata-Andi'a J, Naves-Di'az M. The role of paricalcitol in chronic kidney disease. Eur Nephrol 2011;5:82-90.
8. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. The role of paricalcitol on proteinuria. J Ren Care 2011;37:80-84.
9. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;76:S1-130.
10. Mizobuchi M, Morrissey J, Finch JL etal. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796-1806.
11. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008;105:15896-152009901.
12. Freundlich M, Quiroz Y, Zhang Z etal. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394-1402.
13. Deb DK, Sun T, Wong KE etal. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 2010;77:1000-1009.
14. He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011;22:90-103.
15. Finch JL, Suarez EB, Husain K etal. Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol 2012;302:F141-149.
16. Agarwal R, Acharya M, Tian J etal. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68:2823-2828.
17. Alborzi P, Patel NA, Peterson C etal. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52:249-255.
18. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009;54:647-652.
19. de Zeeuw D, Agarwal R, Amdahl M etal. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-1551.
20. Larsen T, Mose F, Bech J, Pedersen E. Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial. J Am Soc Nephrol 2012;23:1046A.
21. Joergensen C, Tarnow L, Goetze J, Rossing P. Vitamin D analogue therapy, cardiovascular risk and kidney function in type 1 diabetic patients with diabetic nephropathy: a randomized trial. J Am Soc Nephrol 2012;23:218A.
22. De Nicola L, Conte G, Russo D, Gorini A, Minutolo R. Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study. BMC Nephrol 2012;13:150.